BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk

36Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The BRCA2 372 HH genotype defined by the BRCA2 N372H nonconservative amino acid substitution polymorphism was recently reported to be associated with a small increased risk of breast cancer. We investigated whether this polymorphism was associated with ovarian cancer risk by conducting British and Australian case-control comparisons in parallel, including a total sample of 1,121 ovarian cancer cases and 2,643 controls. There was no difference in genotype frequency between control groups from the 2 studies (p = 0.9). The HH genotype was associated with an increased risk of ovarian cancer in both studies, and the risk estimate for the pooled studies was 1.36 (95% CI 1.04-1.77, p = 0.03). There was also a suggestion that this risk may be greater for ovarian cancers of the serous subtype for both studies, with an OR (95% CI) of 1.66 (1.17-2.54) for the 2 studies combined (p = 0.005). The BRCA2 372 HH genotype appears to be associated with an increased risk of ovarian cancer of a similar magnitude to that reported for breast cancer. © 2002 Wiley-Liss, Inc.

Author supplied keywords

Cite

CITATION STYLE

APA

Auranen, A., Spurdle, A. B., Chen, X., Lipscombe, J., Purdie, D. M., Hopper, J. L., … Novik, K. L. (2003). BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk. International Journal of Cancer, 103(3), 427–430. https://doi.org/10.1002/ijc.10814

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free